🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesCoronary artery calcium score changes on GLP-1 — what worked for you?

Coronary artery calcium score changes on GLP-1 — what worked for you?

kate.chem Tue, Mar 10, 2026 at 4:22 AM 10 replies 783 viewsPage 1 of 2
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Mar 10, 2026 at 4:22 AM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

The narrow version of the question is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Practical detail welcome, however dull — the duller the better.

31 9steve_okc, dave_SLC, FDA_TrackerJim and 28 others
Reply Quote Save Share Report
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Mar 10, 2026 at 6:00 AM#2
kate.chem said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

32 10RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 29 others
Reply Quote Save Share Report
nancy_portland
Member
345
1,567
Aug 2024
Portland, ME
Mar 10, 2026 at 7:38 AM#3
DebRD_ATL said:
Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: Mar 10, 2026 at 8:38 AM
33 11MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 30 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Mar 10, 2026 at 9:16 AM#4
kate.chem said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Second this.

34 12jennifer_SEA, tyler_CSCS, VanRx_Mike and 31 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Mar 10, 2026 at 6:53 PM#5

From the other side of the consultation, briefly.

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 7.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 1.5 mg/L (moderate risk)
Month 12 hsCRP: 0.6 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 14% to 4%. My cardiologist is genuinely impressed.

Last edited: Mar 10, 2026 at 9:53 PM
35 13amy_econ_NJ, bbq_ray_KC, oliver_london and 32 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register